Literature DB >> 20705479

The long term immunological response of swine after two exposures to a salmon thrombin and fibrinogen hemostatic bandage.

Stephen W Rothwell1, Timothy Settle, Shannon Wallace, Jennifer Dorsey, David Simpson, James R Bowman, Paul Janmey, Evelyn Sawyer.   

Abstract

Experimental salmon thrombin/fibrinogen dressings have been shown to provide effective hemostasis in severe hemorrhage situations. The hypothesis for this study was that swine would still remain healthy without coagulopathy six months after exposure to salmon thrombin/fibrinogen dressings. Initial exposure was by insertion of the salmon dressing into the peritoneal cavity. Three months after the initial exposure, the same animals were subjected to two full thickness dermal wounds on the dorsal surface. One wound was bandaged with the salmon thrombin/fibrinogen bandage and the other wound was dressed with a standard bandage. The animals were monitored for an additional three months. Blood was drawn every 14 days over the six months for immunological and coagulation function analysis. All of the animals (8 pigs) remained healthy during the six month period and the dermal wounds healed without incidence. Lymph nodes and spleen showed signs of normal immune response and Western blots showed development of antibodies against salmon fibrinogen, but none of the animals made antibodies that recognized any species of thrombin. Coagulation parameters (fibrinogen concentration, thrombin time, PT and aPTT) and hematological parameters remained normal over the course of the study when compared to initial values of the subject swine. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705479      PMCID: PMC3930570          DOI: 10.1016/j.biologicals.2010.07.001

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  42 in total

1.  Effect of TachoSil in a coagulopathic pig model with blunt liver injuries.

Authors:  Oliver Grottke; Till Braunschweig; Nora Daheim; Marc Coburn; Gerrit Grieb; Rolf Rossaint; Rene Tolba
Journal:  J Surg Res       Date:  2010-03-04       Impact factor: 2.192

Review 2.  Immune response to biologic scaffold materials.

Authors:  Stephen F Badylak; Thomas W Gilbert
Journal:  Semin Immunol       Date:  2008-02-20       Impact factor: 11.130

Review 3.  Active and mechanical hemostatic agents.

Authors:  William D Spotnitz
Journal:  Surgery       Date:  2007-10       Impact factor: 3.982

Review 4.  Evolution of fibrinogen-coated collagen patch for use as a topical hemostatic agent.

Authors:  Deha Erdogan; Thomas M van Gulik
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2008-04       Impact factor: 3.368

5.  Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin.

Authors:  Jeffrey L Ballard; Fred A Weaver; Neil K Singla; William C Chapman; W Allan Alexander
Journal:  J Am Coll Surg       Date:  2009-12-14       Impact factor: 6.113

Review 6.  Massive transfusion and nonsurgical hemostatic agents.

Authors:  Jeremy G Perkins; Andrew P Cap; Brendan M Weiss; Thomas J Reid; Charles D Bolan; Charles E Bolan
Journal:  Crit Care Med       Date:  2008-07       Impact factor: 7.598

Review 7.  Granulomatous foreign-body reaction involving oral and perioral tissues after injection of biomaterials: a series of 7 cases and review of the literature.

Authors:  Bruno C Jham; Nikolaos G Nikitakis; Mark A Scheper; John C Papadimitriou; Bernard A Levy; Helen Rivera
Journal:  J Oral Maxillofac Surg       Date:  2009-02       Impact factor: 1.895

8.  Comparison of new hemostatic granules/powders with currently deployed hemostatic products in a lethal model of extremity arterial hemorrhage in swine.

Authors:  Bijan S Kheirabadi; Jason W Edens; Irasema B Terrazas; J Scot Estep; Harold G Klemcke; Michael A Dubick; John B Holcomb
Journal:  J Trauma       Date:  2009-02

Review 9.  Mucocutaneous Splendore-Hoeppli phenomenon.

Authors:  Mahmoud R Hussein
Journal:  J Cutan Pathol       Date:  2008-11       Impact factor: 1.587

10.  Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004.

Authors:  John B Holcomb; Neil R McMullin; Lisa Pearse; Jim Caruso; Charles E Wade; Lynne Oetjen-Gerdes; Howard R Champion; Mimi Lawnick; Warner Farr; Sam Rodriguez; Frank K Butler
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

View more
  3 in total

1.  The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury.

Authors:  Christine L Weisshaar; Jessamine P Winer; Benjamin B Guarino; Paul A Janmey; Beth A Winkelstein
Journal:  Biomaterials       Date:  2011-09-22       Impact factor: 12.479

2.  Salmon fibrin treatment of spinal cord injury promotes functional recovery and density of serotonergic innervation.

Authors:  Kelli G Sharp; Amanda R Dickson; Steve A Marchenko; Kelly M Yee; Pauline N Emery; Ivo Laidmåe; Raivo Uibo; Evelyn S Sawyer; Oswald Steward; Lisa A Flanagan
Journal:  Exp Neurol       Date:  2012-03-05       Impact factor: 5.330

Review 3.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.